title: RNAi-Based Therapy in Experimental Ischemia-Reperfusion Injury. The New Targets.
abstract: Ischemia reperfusion injury is an important pathophysiological process in many fields such as transplantation, stroke, atherosclerosis, trauma and myocardial infarction. Recent advances in gene silencing may help to reduce ischemic effects, targeting molecules related to this pathological process.
  
  
  
  Here, we review the different silencing approaches in ischemic injury, highlighting the role of co-stimulatory molecules in renal transplantation.
  
  
  
  Gene silencing appears as a new strategy to prevent the inflammation and injury associated with ischemia.
authors: Laura
authors: L
authors: de Ramon
authors: Marta
authors: M
authors: Jarque
authors: Elia
authors: E
authors: Ripoll
authors: Oriol
authors: O
authors: Bestard
authors: Josep M
authors: JM
authors: Grinyo
authors: Experimental Nephrology, Departament de Ciències Clíniques, Universitat de Barcelona, Institut d'investigació biomedica de Bellvitge (IDIBELL), Hospitalet Llobregat, Barcelona, Spain. jtorras@bellvitgehospital.cat.
authors: Juan
authors: J
authors: Torras
mesh_terms: D058186:Acute Kidney Injury / Q000235:genetics / Q000628:therapy*; D020868:Gene Silencing; D006801:Humans; D007249:Inflammation / Q000235:genetics / Q000628:therapy*; D007511:Ischemia / Q000235:genetics / Q000628:therapy*; D012333:RNA, Messenger / Q000235:genetics*; D000067492:RNAi Therapeutics; D015427:Reperfusion Injury / Q000235:genetics / Q000628:therapy*
chemical_list: D012333:RNA, Messenger